Analysis included 234 patients with early symptomatic Alzheimer disease initiating lecanemab (Aug. 1, 2023, to Oct. 1, 2024). The researchers found that infusion-related reactions occurred in 37 ...

Proposed intravenous maintenance dosing application to reduce lecanemab infusion frequency from every two weeks to every four weeks for eligible adult UK patients after initial 18 months of treatment ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) ...

Viehbacher, “Biogen”) announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi ® (lecanemab) Marketing Authorization (MA) in the ...

The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms. The European Commission announced on ...

The European Commission announced on Tuesday the approval of the antibody lecanemab to treat Alzheimer's. Lecanemab is intended for treatment in the early stages and is the first medication of its ...

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early Alzheimer's disease, initial findings from the CLARITY AD ...

Since receiving approval from the U.S. Food and Drug Administration in 2023 as only the second Alzheimer’s-modifying drug, sales of lecanemab, marketed as Leqembi, have consistently increased ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily ...

They found that indeed lecanemab was probably less effective in females than males in the Phase 3 trial. However, there was insufficient evidence to say the drug was totally ineffective in females.

New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...